KR-27452

• Description:

  KR-27452 is a selective and orally active PI4KIIIβ inhibitor with an IC50 of 0.026 μM, while showing no activity against PI4KIIIα (IC50 >10 μM) . KR-27452 specifically binds to and inhibits PI4KIIIβ, leading to reduced viral replication in cells. KR-27452 exhibits strong antiviral activity against human rhinovirus (RVs) and Coxsackievirus (COXs) . KR-27452 can be used for the research of infection[1].

• UNSPSC:

  12352005

• Target:

  Enterovirus; PI4K

• Related Pathways:

  Anti-infection; PI3K/Akt/mTOR

• Applications:

  COVID-19-anti-virus

• Field of Research:

  Infection

• Smiles:

  O=C (N (CCCO) C) C1=CC (C2=C (C) N=C (NC (CC3=CC=CC=C3) =O) S2) =CC=C1OC

• Molecular Formula:

  C24H27N3O4S

• Molecular Weight:

  453.55

• References & Citations:

  [1]Ayele SA, et al. 2-amido-3-aryl-4-methyl-thiazole derivatives as broad-spectrum anti-rhinoviral agents. Eur J Med Chem. 2026;302 (Pt 3) :118318.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  PI4KIIIβ